NASDAQ:NVCN - Neovasc Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.0429 0.00 (0.00 %)
(As of 06/24/2018 04:00 PM ET)
Previous Close$0.0429
Today's Range$0.0410 - $0.0449
52-Week Range$0.03 - $1.89
Volume85.15 million shs
Average Volume35.16 million shs
Market Capitalization$70.69 million
P/E Ratio-0.12
Dividend YieldN/A
Neovasc logoNeovasc Inc., a specialty medical device company, develops, manufactures, and markets cardiovascular devices worldwide. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company also provides Peripatch tissue products. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.

Receive NVCN News and Ratings via Email

Sign-up to receive the latest news and ratings for NVCN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments


Debt-to-Equity Ratio-0.73
Current Ratio0.92
Quick Ratio0.90


Trailing P/E Ratio-0.12
Forward P/E Ratio-0.23
P/E GrowthN/A

Sales & Book Value

Annual Sales$5.39 million
Price / Sales14.81
Cash FlowN/A
Price / CashN/A
Book Value($0.46) per share
Price / Book-0.09


EPS (Most Recent Fiscal Year)($0.37)
Net Income$-22,900,000.00
Net Margins-1,687.90%
Return on Equity-85.81%
Return on Assets-52.15%


Outstanding Shares1,860,190,000

The Truth About Cryptocurrencies

Neovasc (NASDAQ:NVCN) Frequently Asked Questions

What is Neovasc's stock symbol?

Neovasc trades on the NASDAQ under the ticker symbol "NVCN."

How were Neovasc's earnings last quarter?

Neovasc Inc (NASDAQ:NVCN) released its earnings results on Thursday, May, 10th. The medical equipment provider reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.01) by $0.10. The medical equipment provider earned $0.34 million during the quarter, compared to the consensus estimate of $1.16 million. Neovasc had a negative net margin of 1,687.90% and a negative return on equity of 85.81%. View Neovasc's Earnings History.

When is Neovasc's next earnings date?

Neovasc is scheduled to release their next quarterly earnings announcement on Thursday, August, 9th 2018. View Earnings Estimates for Neovasc.

What price target have analysts set for NVCN?

2 Wall Street analysts have issued 1-year price targets for Neovasc's stock. Their forecasts range from $0.50 to $2.00. On average, they anticipate Neovasc's stock price to reach $1.25 in the next year. View Analyst Ratings for Neovasc.

Are investors shorting Neovasc?

Neovasc saw a increase in short interest during the month of May. As of May 31st, there was short interest totalling 97,894,894 shares, an increase of 34.2% from the May 15th total of 72,937,221 shares. Based on an average trading volume of 86,750,166 shares, the days-to-cover ratio is currently 1.1 days. View Neovasc's Current Options Chain.

Who are some of Neovasc's key competitors?

Who are Neovasc's key executives?

Neovasc's management team includes the folowing people:
  • Mr. Christopher Clark, CFO & Corp. Sec. (Age 46)
  • Mr. Brian McPherson, Chief Operating Officer (Age 56)
  • Ms. Vicki Bebeau, VP of Clinical and Regulatory Affairs
  • Mr. Randy Lane, VP of R&D
  • Mr. Alexei J. Marko, Advisor & Director (Age 49)

Has Neovasc been receiving favorable news coverage?

News coverage about NVCN stock has trended somewhat positive this week, Accern reports. Accern scores the sentiment of news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Neovasc earned a news sentiment score of 0.03 on Accern's scale. They also assigned media coverage about the medical equipment provider an impact score of 44.15 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Who are Neovasc's major shareholders?

Neovasc's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Gagnon Securities LLC (0.35%). View Institutional Ownership Trends for Neovasc.

Which institutional investors are buying Neovasc stock?

NVCN stock was bought by a variety of institutional investors in the last quarter, including Gagnon Securities LLC. View Insider Buying and Selling for Neovasc.

How do I buy shares of Neovasc?

Shares of NVCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Neovasc's stock price today?

One share of NVCN stock can currently be purchased for approximately $0.0429.

How big of a company is Neovasc?

Neovasc has a market capitalization of $70.69 million and generates $5.39 million in revenue each year. The medical equipment provider earns $-22,900,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. Neovasc employs 147 workers across the globe.

How can I contact Neovasc?

Neovasc's mailing address is Suite 5138 - 13562 Maycrest Way, Richmond A1, V6V 2J7. The medical equipment provider can be reached via phone at 604-270-4344 or via email at [email protected]

MarketBeat Community Rating for Neovasc (NVCN)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  202 (Vote Outperform)
Underperform Votes:  171 (Vote Underperform)
Total Votes:  373
MarketBeat's community ratings are surveys of what our community members think about Neovasc and other stocks. Vote "Outperform" if you believe NVCN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVCN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/24/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.